These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1796130)

  • 1. Mood responses of remitted schizophrenics to methylphenidate infusion.
    Robinson D; Mayerhoff D; Alvir J; Cooper T; Lieberman J
    Psychopharmacology (Berl); 1991; 105(2):247-52. PubMed ID: 1796130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylphenidate challenge as a predictor of relapse in schizophrenia.
    Lieberman JA; Kane JM; Gadaleta D; Brenner R; Lesser MS; Kinon B
    Am J Psychiatry; 1984 May; 141(5):633-8. PubMed ID: 6143506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral and biochemical effects of methylphenidate in schizophrenic and nonschizophrenic patients.
    Sharma RP; Javaid JI; Pandey GN; Janicak PG; Davis JM
    Biol Psychiatry; 1991 Sep; 30(5):459-66. PubMed ID: 1657221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Schizoaffective disorder: a form of schizophrenia or affective disorder?
    Evans JD; Heaton RK; Paulsen JS; McAdams LA; Heaton SC; Jeste DV
    J Clin Psychiatry; 1999 Dec; 60(12):874-82. PubMed ID: 10665641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral response to methylphenidate and treatment outcome in first episode schizophrenia.
    Jody D; Lieberman JA; Geisler S; Szymanski S; Alvir JM
    Psychopharmacol Bull; 1990; 26(2):224-30. PubMed ID: 2236460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia.
    McElroy SL; Dessain EC; Pope HG; Cole JO; Keck PE; Frankenberg FR; Aizley HG; O'Brien S
    J Clin Psychiatry; 1991 Oct; 52(10):411-4. PubMed ID: 1938976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylphenidate augmentation therapy in schizophrenia.
    Carpenter MD; Winsberg BG; Camus LA
    J Clin Psychopharmacol; 1992 Aug; 12(4):273-5. PubMed ID: 1527231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schizoaffective disorders are psychotic mood disorders; there are no schizoaffective disorders.
    Lake CR; Hurwitz N
    Psychiatry Res; 2006 Aug; 143(2-3):255-87. PubMed ID: 16857267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysphoria associated with methylphenidate infusion in borderline personality disorder.
    Lucas PB; Gardner DL; Wolkowitz OM; Cowdry RW
    Am J Psychiatry; 1987 Dec; 144(12):1577-9. PubMed ID: 3688282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donepezil effects on mood in patients with schizophrenia and schizoaffective disorder.
    Risch SC; Horner MD; McGurk SR; Palecko S; Markowitz JS; Nahas Z; DeVane CL
    Int J Neuropsychopharmacol; 2006 Oct; 9(5):603-5. PubMed ID: 16202177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of sodium nitroprusside on psychotic symptoms and spatial working memory in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial.
    Stone JM; Morrison PD; Koychev I; Gao F; Reilly TJ; Kolanko M; Mohammadinasab A; Kapur S; McGuire PK
    Psychol Med; 2016 Dec; 46(16):3443-3450. PubMed ID: 27655012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia.
    Fenton WS; Dickerson F; Boronow J; Hibbeln JR; Knable M
    Am J Psychiatry; 2001 Dec; 158(12):2071-4. PubMed ID: 11729030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
    Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia.
    Krystal JH; Seibyl JP; Price LH; Woods SW; Heninger GR; Aghajanian GK; Charney DS
    Arch Gen Psychiatry; 1993 Aug; 50(8):624-35. PubMed ID: 8102048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A family study of DSM-III-R schizoaffective disorder, depressive type, compared with schizophrenia and psychotic and nonpsychotic major depression.
    Maj M; Starace F; Pirozzi R
    Am J Psychiatry; 1991 May; 148(5):612-6. PubMed ID: 2018162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of schizoaffective disorders.
    Goodnick PJ; Meltzer HY
    Schizophr Bull; 1984; 10(1):30-48. PubMed ID: 6142525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the borders of the schizoaffective spectrum: a categorical and dimensional approach.
    Peralta V; Cuesta MJ
    J Affect Disord; 2008 May; 108(1-2):71-86. PubMed ID: 18029027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of schizoaffective disorder and schizophrenia with mood symptoms.
    Levinson DF; Umapathy C; Musthaq M
    Am J Psychiatry; 1999 Aug; 156(8):1138-48. PubMed ID: 10450252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia.
    Lieberman JA; Alvir J; Geisler S; Ramos-Lorenzi J; Woerner M; Novacenko H; Cooper T; Kane JM
    Neuropsychopharmacology; 1994 Oct; 11(2):107-18. PubMed ID: 7840862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial.
    Kulkarni J; Gavrilidis E; Gwini SM; Worsley R; Grigg J; Warren A; Gurvich C; Gilbert H; Berk M; Davis SR
    JAMA Psychiatry; 2016 Sep; 73(9):947-54. PubMed ID: 27438995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.